Abstract
Pain is a common non-motor symptom of Parkinson’s disease (PD), which often occurs in the early disease stages. Despite the high prevalence, it remains inadequately treated. In a hemi-parkinsonian rat model, we aimed to investigate the neurochemical factors involved in orofacial pain development, with a specific focus on pain-related peptides and cannabinoid receptors. We also evaluated whether treadmill exercise could improve orofacial pain and modulate these mechanisms. Rats were unilaterally injected in the striatum with either 6-hydroxydopamine (6-OHDA) or saline. Fifteen days after stereotactic surgery, the animals were submitted to treadmill exercise (EX), or remained sedentary (SED). Pain assessment was performed before the surgical procedure and prior to each training session. Pain-related peptides, substance P (SP), calcitonin gene-related peptide (CGRP), and transient receptor potential vanilloid type 1 (TRPV1) activation and cannabinoid receptor type 1 (CB1) and type 2 (CB2) were evaluated in the trigeminal nucleus. In order to confirm the possible involvement of cannabinoid receptors, we also injected antagonists of CB1 and CB2 receptors. We confirmed the presence of orofacial pain after unilateral 6-OHDA-injection, which improved after aerobic exercise training. We also observed increased pain-related expression of SP, CGRP and TRPV1 and decreased CB1 and CB2 in the trigeminal ganglion and caudal spinal trigeminal nucleus in animals with PD, which was reversed after aerobic exercise training. In addition, we confirm the involvement of cannabinoid receptors since both antagonists decreased the nociceptive threshold of PD animals. These data suggest that aerobic exercise effectively improved the orofacial pain associated with the PD model, and may be mediated by pain-related neuropeptides and cannabinoid receptors in the trigeminal system.
Keywords: 6-OHDA, Parkinson’s disease, Rats, Treadmill exercise, Trigeminal pain
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Adewusi JK, Hadjivassiliou M, Vinagre-Aragon A, O’Connor KR, Khan A, Grunewald RA, Zis P (2018) Sensory neuropathic symptoms in idiopathic Parkinson’s disease: prevalence and impact on quality of life. Acta Neurologica Belgica 118(3):445–450. https://doi.org/10.1007/s13760-018-0947-3 – DOI – PubMed
-
- Akerman S, Kaube H, Goadsby PJ (2004) Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther 309(1):56–63. https://doi.org/10.1124/jpet.103.059808 – DOI – PubMed
-
- Barrot M (2012) Tests and models of nociception and pain in rodents. Neurosci 211(39):50 S0306-4522(11)01438-2. https://doi.org/10.1016/j.neuroscience.2011.12.041
-
- Basavarajappa BS, Shivakumar M, Joshi V, Subbanna S (2017) Endocannabinoid system in neurodegenerative disorders. J Neurochem 142(5):624–648. https://doi.org/10.1111/jnc.14098
-
- Binda KH, Real CC, Ferreira AFF, Britto LRG, Chacur M (2019) Antinociceptive effects of treadmill exercise in a rat model of Parkinson’s disease: the role of cannabinoid and opioid receptors. Brain Res 46521. https://doi.org/10.1016/j.brainres.2019.146521